What is Theravance Biopharma's EV / EBITDA?

Theravance Biopharma (TBPH) reported EV / EBITDA of 199.8× in Q1 2026.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Theravance Biopharma TBPH EV / EBITDA

EV / EBITDA at other companies

Zevra Therapeutics, Inc.ZVRA

171.7×—

Royalty PharmaRPRX

13.9×+1.7×

Aurinia PharmaceuticalsAUPH

14×-8.7×

OrganonOGN

8×-1.0×

Mirum Pharmaceuticals, Inc.MIRM

1,820.6×—

Bristol-Myers SquibbBMY

12×+0.4×

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

enterprise value/ebitda=199.8×

Based on the most recent quarter.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's EV / EBITDA?: Theravance Biopharma (TBPH) reported EV / EBITDA of 199.8× in Q1 2026.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.